How Inflammation Impacts CIRS

MMP-9 and Tissue Inflammation

 

 

Matrix metalloproteinase-9 (MMP-9) is an enzyme involved in breaking down and remodeling the extracellular matrix—the structural framework surrounding cells and tissues. It is released by immune cells including neutrophils and macrophages during inflammation and plays a normal role in wound healing, immune-cell movement, and tissue repair. 

 

In CIRS, persistent innate immune activation and inflammatory signaling can drive MMP-9 higher than normal, making it one of the inflammatory markers commonly evaluated alongside other CIRS-related biomarkers. Elevated MMP-9 can therefore provide another clue that inflammatory and tissue-remodeling pathways remain activated and can be followed over time to see whether that pattern improves with treatment. 

 

MMP-9 is particularly relevant neurologically because excessive activity can degrade components of the extracellular matrix and vascular basement membrane that help maintain the blood-brain barrier. Higher MMP-9 activity has been associated with increased blood-brain barrier permeability in several inflammatory and neurological conditions, potentially allowing circulating inflammatory mediators and immune cells greater access to the brain environment. 

 

However, MMP-9 isn’t specific to CIRS. It can rise with infections, autoimmune and inflammatory diseases, vascular injury, neurological disease, tissue damage, Lyme, mast cell activation syndrome (MCAS), and other inflammatory stressors, so an elevated result alone can’t diagnose mold illness or CIRS by itself. Broader physiologic stress and toxic or infectious exposures may also contribute indirectly by increasing inflammatory signaling.

 

Pro-Tip: Elevated MMP-9 can sometimes normalize as the underlying CIRS drivers are addressed, so treatment should focus first on correcting the causes of chronic inflammation rather than chasing the laboratory value alone. In our practice, we may also consider anti-inflammatory and pro-resolving support such as high-quality omega-3 fish oils and specialized pro-resolving mediators (SPMs); omega-3 interventions have reduced MMP-9 in some clinical and experimental settings, although results aren’t consistent across all populations. We also commonly recommend a high-fat Carnivore diet to support metabolic health and reduce dietary inflammatory inputs. VIP therapy may also help normalize the broader inflammatory and neuroimmune pattern, including elevated MMP-9 as the illness resolves.

 

TGF-β1 and Immune Regulation

 

 

Transforming growth factor beta-1 (TGF-β1) is a signaling protein involved in immune regulation, tissue repair, cell growth, and remodeling. With CIRS, elevated TGF-β1 is commonly evaluated as a marker of persistent immune dysregulation. Abnormal TGF-β signaling can disrupt the balance between regulatory T cells and inflammatory Th17 responses, while prolonged elevation can promote excessive tissue remodeling and fibrosis, making stubborn elevations important to address rather than viewing them as inflammation alone. 

 

Like the other CIRS biomarkers, TGF-β1 isn’t specific to CIRS. 

 

Levels may be influenced by acute infection or illness, tissue healing, pregnancy, autoimmune disease, inflammatory bowel disease, asthma and chronic lung conditions, liver disease, acute Lyme disease, and other inflammatory or environmental stressors. This is why we never interpret TGF-β1 in isolation. 

 

In some CIRS patients, levels improve after exposure removal and adequate treatment with prescription binders such as cholestyramine or Welchol; when abnormalities persist, later stages of the Shoemaker Protocol address this pathway, and published CIRS research has reported improvement in TGF-β1 with intranasal VIP therapy. 

 

Pro-Tip: If TGF-β1 remains elevated, it’s worth looking for additional inflammatory or environmental contributors rather than simply treating the marker. Depending on the individual, supportive options we may consider include zinc, resveratrol, L-carnitine, sunlight/UV exposure, black cumin seed oil, or other targeted therapies; compounds such as berberine can have antimicrobial effects and should be discussed with a practitioner before use. Environmental exposures, including agricultural chemicals such as atrazine, may also warrant consideration when clinically relevant.

 

VEGF and Tissue Oxygenation

 

 

Vascular endothelial growth factor (VEGF) is a signaling protein that helps stimulate new blood-vessel formation and improve vascular supply when tissues are not receiving enough oxygen. Low oxygen stabilizes hypoxia-inducible factor (HIF), which in turn stimulates VEGF production as part of the body’s attempt to restore blood flow and oxygen delivery. 

 

Inflammatory activity can impair microcirculation and tissue oxygenation. VEGF may initially rise in response to this hypoxic stress and then become abnormally low in some patients. When VEGF is low, reduced microvascular support may contribute to poorer tissue oxygen delivery, earlier reliance on anaerobic metabolism, mitochondrial stress, reduced exercise tolerance, and post-exertional fatigue.

 

VEGF is checked in CIRS to help assess this vascular and oxygenation component of the illness and to follow whether it normalizes with treatment, but abnormal VEGF also isn’t specific to CIRS. VEGF can be elevated in cancer, inflammatory and vascular diseases, tissue injury, mast cell dysregulation, MCAS, and other states involving hypoxia or angiogenesis, so it must be interpreted alongside symptoms and the rest of the CIRS panel.

 

In the Shoemaker Protocol, abnormal VEGF may improve as exposure, inflammation, and other upstream abnormalities are addressed; if it remains low, carefully progressed exercise may be introduced to stimulate vascular adaptation, while later-stage intranasal VIP and other individualized supports may also be considered.

 

MSH and Inflammatory Regulation

 

 

Melanocyte-stimulating hormone (MSH) is a neuroregulatory hormone involved in inflammatory control, sleep, pain signaling, hormonal balance, fluid regulation, and immune function. Inflammatory cytokines can disrupt leptin signaling and contribute to abnormally low MSH. 

 

Low MSH is associated with a wide range of downstream effects, including disturbed sleep and melatonin rhythms, abnormalities in ADH/AVP and osmolality that may contribute to excessive thirst and urination, increased inflammatory signaling and T-cell dysregulation, greater pain sensitivity, impaired gut-barrier function, lower androgen levels, leptin-related weight gain, and increased susceptibility to nasal colonization with MARCoNS.

 

MSH is evaluated because it provides another window into the neuroimmune and hormonal dysregulation that can accompany CIRS, but it should be interpreted alongside symptoms and the broader biomarker pattern. Low VIP is also commonly described within the CIRS biotoxin pathway, and later-stage intranasal VIP therapy may help improve downstream regulatory abnormalities, including low MSH, as the broader inflammatory response resolves.

 

Pro-Tip: Theoretically, there may be alternative ways to support low MSH, but in our clinical practice this can be one of the more stubborn markers. We sometimes see MSH remain below the expected range even in patients who have successfully completed CIRS treatment, feel well, and are clinically in remission. Some of our patients and clients have also experimented with peptides intended to support MSH signaling, but these individual n=1 experiences have produced mixed results—another reason we prioritize the patient’s overall recovery rather than chasing a single laboratory value.

 

ADH, Osmolality, and Fluid Regulation

 

 

Antidiuretic hormone (ADH), also called vasopressin, helps the kidneys regulate how much water the body retains, while serum osmolality reflects how concentrated the blood is based largely on water, sodium, glucose, and other dissolved particles. Normally, rising osmolality stimulates ADH release so the kidneys conserve water and concentrate the urine. 

 

Disrupted neuroendocrine signaling can create an inappropriate relationship between ADH and osmolality, contributing to excessive thirst, frequent urination, nighttime urination, dehydration, fluctuations in sodium, dizziness, palpitations, and orthostatic or POTS-like symptoms. 

 

Rather than interpreting either value alone, CIRS practitioners commonly look at ADH in relation to serum osmolality and follow the pattern as treatment progresses. Abnormalities aren’t specific to CIRS and can occur with dehydration, kidney disease, medications, endocrine disorders, head injury, diabetes insipidus, SIADH, and other conditions affecting fluid balance, making the broader clinical context essential. 

 

Pro-Tip: In our clinical experience, ADH and osmolality abnormalities often improve on their own as exposure and the broader CIRS inflammatory response are successfully treated. We also see some Carnivore and keto dieters who struggle to balance electrolytes no matter how much sodium, potassium, or magnesium they adjust; in some cases, eating fewer carbs and retaining less water may simply unmask an underlying ADH/osmolality problem that was already affecting fluid regulation. For persistent electrolyte, excessive thirst, or frequent urination concerns, we offer ADH and osmolality testing to help determine whether impaired water balance may be contributing.

 

For stubborn symptoms, desmopressin, a prescription medication that mimics vasopressin and reduces urinary water loss, may be considered in select cases, although we have seen mixed results. Since desmopressin can cause excessive water retention and potentially dangerous low sodium, it requires appropriate clinician supervision and electrolyte monitoring.

 

How Inflammation Impacts the Brain in CIRS

In CIRS, chronic inflammatory signaling can extend beyond the immune system and affect the brain, disrupting neurological function, hormone regulation, blood flow, and the body’s ability to maintain normal cognitive and autonomic balance.

 

Neuroinflammation and Related Symptoms

 

 

Neuroinflammation refers to inflammatory activity within the brain and central nervous system. Continual systemic immune activation can contribute to inflammatory signaling that affects neurological function, helping explain why cognitive and sensory symptoms are commonly such a prominent part of the illness. Published CIRS research has documented neurological and executive-function complaints alongside measurable brain-volume differences in patients exposed to water-damaged buildings. 

 

For patients, this may show up as brain fog, difficulty concentrating or finding words, short-term memory problems, headaches, dizziness, altered sensation, or reduced mental stamina.

 

Inflammation and the Blood-Brain Barrier

 

 

The blood-brain barrier (BBB) is a highly selective protective layer that regulates what can move from the bloodstream into the brain. During persistent inflammation, cytokines and enzymes such as MMP-9 can disrupt the tight junctions and structural proteins that help maintain this barrier, increasing its permeability. When that happens, inflammatory mediators and immune cells may gain greater access to the brain environment and further amplify neuroinflammation. 

 

This increased permeability is another way ongoing systemic inflammation can have more pronounced neurological effects. A compromised BBB may allow peripheral immune activity to interact more directly with the central nervous system, making it harder for neurological inflammation to fully settle.

 

Inflammation, Mood, and Stress Tolerance

 

 

Constant inflammation can also influence the brain systems involved in mood, motivation, and the stress response. Pro-inflammatory cytokines such as IL-6 and TNF-α can affect neurotransmitter signaling and activate stress-responsive hormonal pathways, which may contribute to irritability, anxiety, low mood, emotional volatility, or a reduced ability to tolerate everyday stress.

 

For someone with CIRS, this means emotional symptoms may be partly intertwined with the underlying inflammatory state rather than existing as a completely separate issue. Chronic inflammation and stress can also influence one another bidirectionally, potentially making patients feel more easily overwhelmed or less resilient during periods of symptom flares. 

 

CIRS, Limbic System, and Nervous System Dysregulation

 

 

The limbic system includes interconnected brain regions involved in threat detection, memory, emotional processing, and regulation of the stress response. These circuits communicate closely with the hypothalamus and autonomic nervous system, helping determine whether the body shifts toward sympathetic fight-or-flight activity or returns toward a parasympathetic rest-and-repair state. Persistent inflammatory signaling can influence these same brain networks, creating a physiological environment in which the brain becomes more sensitive to internal symptoms and perceived environmental threats. 

 

Within CIRS, ongoing inflammation, repeated symptom flares, disrupted sleep, and prior reactions to water-damaged environments may reinforce this threat response over time. The nervous system can become increasingly reactive, making it harder to shift out of survival mode even as other aspects of the illness improve. 

 

Pro-Tip: Our private practice, Empower Functional Health, developed our comprehensive Wholeness Method mind-body program specifically to support complex chronic illness cases like CIRS. With dozens of personalized tools and supports, you can create the right nervous system regulation plan to better support yourself through treatment and beyond.    

 

How CIRS Inflammation Impacts Energy and Mitochondrial Function

 

 

Mitochondria are responsible for producing most of the body’s usable cellular energy in the form of ATP. Consistent inflammatory signaling can interfere with this process by disrupting the mitochondrial electron transport chain and oxidative phosphorylation, reducing how efficiently cells convert nutrients and oxygen into energy. 

 

Cytokines such as TNF-α and IL-1β have been shown to impair mitochondrial respiration and ATP production, which may help explain the profound loss of energy and reduced stamina that can accompany chronic inflammatory states. 

 

Inflammation can also increase mitochondrial production of reactive oxygen species, creating oxidative stress that further damages mitochondrial membranes, proteins, and mitochondrial DNA. As mitochondrial function declines, damaged mitochondria can release additional inflammatory signals, potentially reinforcing the same immune activation that impaired energy production in the first place. 

 

The relationship between chronic inflammation and reduced cellular energy production in CIRS may contribute to the characteristic sense that the body simply can’t generate or sustain energy normally, even when adequate fuel is available.

 

Pro-Tip: In our clinical practice, some patients and clients report symptomatic benefit from oxygen-based therapies such as hyperbaric oxygen therapy (HBOT) and ozone-based treatments including EBOO. These may be considered complementary adjuncts for supporting energy, oxygen delivery, and overall symptom management in select cases, but they don’t replace foundational CIRS treatment, exposure removal, or addressing the underlying inflammatory drivers.

 

How Inflammation Impacts Hormones and Metabolism in CIRS

Perpetual inflammatory signaling can disrupt the communication networks that regulate hormones and other functions, which may contribute to broader metabolic dysfunction as the illness progresses.

 

Inflammation and Leptin Signaling

 

 

Leptin is a hormone produced primarily by fat cells that signals the hypothalamus to help regulate energy balance and coordinate multiple neuroendocrine functions. Perpetual inflammatory cytokine production interferes with leptin receptor signaling, creating a pattern of leptin resistance in which the brain does not respond normally to the hormone’s signal. As a result, circulating leptin may become elevated even though its downstream signaling is impaired.

 

This disruption matters beyond leptin itself because leptin communicates with other regulatory pathways, including those involved in MSH and hypothalamic function. 

 

Abnormal leptin signaling can therefore become another link between ongoing inflammation and broader neuroendocrine dysregulation, making leptin useful as part of the overall biomarker pattern rather than as a stand-alone marker of CIRS.

 

Pro-Tip: GLP-1 microdosing is currently being explored as a potential adjunct in CIRS, including for patients with leptin resistance and broader metabolic dysregulation. However, GLP-1 medications and other peptides are recommended for everyone, and their use should be highly individualized under the guidance of a knowledgeable practitioner.

 

Inflammation, Appetite, and Weight Changes

 

 

Chronic inflammation can disrupt the brain and hormonal signals that regulate hunger, satiety, and energy balance. Altered leptin signaling and hypothalamic dysfunction may make appetite cues less reliable, contributing to increased hunger or reduced appetite, cravings, difficulty feeling satisfied, and weight changes that do not always respond predictably to diet or exercise. 

 

These effects can vary significantly between patients, with some struggling with resistant weight gain while others unintentionally lose weight or have difficulty maintaining adequate intake as the broader inflammatory illness progresses.

 

Sleep and Circadian Disruption

 

 

Persistent inflammation can interfere with the brain signals that regulate the sleep-wake cycle, including melatonin production, cortisol rhythms, and other circadian cues. This may contribute to difficulty falling asleep, frequent waking, unrefreshing sleep, or feeling tired at the wrong times of day, which can further reduce resilience and make it harder for the body to recover from ongoing inflammatory stress.

 

How CIRS Inflammation Impacts the Gut

 

 

The intestinal lining is highly responsive to immune signaling, so continual inflammation can directly affect the gut barrier. Pro-inflammatory cytokines such as TNF-α, IL-1β, and IFN-γ can disrupt the tight-junction proteins that hold intestinal cells together, increase intestinal permeability, alter the protective mucus layer, and interfere with normal epithelial repair. 

 

As barrier integrity declines, more microbial products and other compounds can interact with immune cells beneath the intestinal lining, potentially generating additional inflammatory signaling and placing further stress on an already activated immune system. 

 

Inflammation can also interfere with the enteric nervous system and gastrointestinal motility, changing how efficiently food moves through the stomach and intestines. Cytokines can alter smooth-muscle contraction and nerve signaling within the digestive tract, while changes in intestinal blood flow and tissue function may further affect digestion and nutrient absorption. 

 

Finally, chronic inflammation can alter the intestinal environment itself, including the composition of the gut microbiome and normal bile-acid signaling. Because bile acids, intestinal microbes, the epithelial barrier, and the immune system continuously influence one another, disruption in one area can reinforce dysfunction in the others. 

 

Why Food Sensitivities, SIBO, SIFO, and Other Gut Infections Can Be Common

 

 

In addition to inflammation, low MSH can contribute to impaired gut-barrier integrity, making the intestinal lining more permeable and reactive. 

 

When that barrier is compromised, food proteins, microbial products, and other compounds can interact more readily with the immune system, which may increase the likelihood of new or worsening food sensitivities. Chronic inflammation’s effects on the gut can create a more vulnerable intestinal environment.

 

That altered terrain may also make it easier for bacteria or fungi to persist where they normally would be kept in check, contributing to conditions such as small intestinal bacterial overgrowth (SIBO), small intestinal fungal overgrowth (SIFO), dysbiosis, or recurrent gut infections.

 

Pro-Tip: CIRS treatment timing matters. Co-infections and comorbidities typically need to be addressed in a specific order based on the individual, and treating everything at once can increase cost, reduce tolerance, and make it harder to know what is actually helping. A personalized sequence can improve effectiveness while minimizing unnecessary interventions and wasted resources.

 

How Inflammation Impacts Muscles, Joints, and Physical Recovery in CIRS

 

 

Constant inflammation can directly affect skeletal muscle by altering protein turnover, mitochondrial energy production, and the signaling required for normal tissue repair. Pro-inflammatory cytokines such as TNF-α and IL-6 can promote catabolic pathways and interfere with muscle regeneration, potentially contributing to weakness, reduced exercise capacity, muscle aches, and slower recovery after physical activity. 

 

Acute inflammation is necessary for normal muscle repair, but when inflammatory signaling remains chronically elevated, the body may have a harder time completing the transition from tissue breakdown to rebuilding. 

 

Similar inflammatory signaling can increase pain sensitivity and contribute to discomfort or stiffness in muscles, connective tissues, and joints. These effects may be compounded by impaired cellular energy production and reduced physical activity during prolonged illness, making patients feel increasingly deconditioned and less exercise-tolerant.

 

Pro-Tip: We recommend tolerated movement and exercise throughout all stages of CIRS rather than waiting until later phases of treatment or for every symptom to resolve. Appropriate movement can support circulation and lactate clearance after exertion, while exercise also increases brain-derived neurotrophic factor (BDNF) and supports neuroplasticity pathways associated with neurogenesis. The key word is tolerated: for one individual this may mean several minutes of slow walking, while another may tolerate resistance training or longer aerobic exercise. The goal is progressive movement that supports recovery without repeatedly triggering significant crashes or prolonged symptom flares.

 

How CIRS Inflammation Impacts the Cardiovascular and Circulatory Systems

 

 

Persistent inflammation can affect the endothelium, the thin layer of cells lining blood vessels that helps regulate vascular tone, blood flow, clotting, and the movement of nutrients and oxygen into tissues. 

 

Pro-inflammatory cytokines can reduce nitric oxide availability and promote endothelial dysfunction, making vessels less able to dilate normally while shifting the vascular environment toward greater inflammation and coagulation. These changes may impair circulation and tissue perfusion even before a conventional cardiovascular diagnosis is present. 

 

These effects may overlap with abnormalities already discussed, including impaired microcirculation, altered VEGF signaling, and inflammatory activation of the vascular system. Inflammation can increase the tendency of white blood cells and platelets to interact with the vessel lining and shift the normal balance between clot formation and breakdown, potentially compromising blood flow through smaller vessels. 

 

The cardiovascular picture in CIRS therefore may reflect more than traditional risk factors alone; inflammatory burden, vascular function, metabolic health, immune activation, and other individual factors can all contribute.

 

Pro-Tip: In our clinical practice, we have seen many patients following strict Carnivore, meat-based, or keto diets whose cardiovascular lab profiles look very different from what we would expect based on their diet and lifestyle alone. This can occur within the broader inflammatory picture of CIRS, and we often see portions of that profile improve as the underlying illness is successfully treated. However, abnormal cardiovascular markers should never automatically be attributed to CIRS or assumed to resolve on their own—depending on the individual, other cardiovascular and lifestyle supports may still be necessary.

 

CIRS Inflammatory Symptoms

 

 

CIRS is classically associated with 37 symptoms organized into 13 symptom clusters, which were grouped statistically rather than by organ system to help identify the characteristic multisystem pattern of biotoxin illness. 

 

These symptoms are understood as downstream manifestations of the biotoxin pathway and various systems impacted; having symptoms across multiple clusters is used as one part of the broader diagnostic assessment.

 

The 13 CIRS symptom clusters include:

 

• Cluster 1: Chronic fatigue
• Cluster 2: Generalized weakness, body aches, headaches, light sensitivity, and difficulty learning or assimilating new information
• Cluster 3: Memory impairment and difficulty finding words
• Cluster 4: Difficulty concentrating or maintaining focus
• Cluster 5: Joint pain, morning stiffness, and muscle cramps
• Cluster 6: Unusual skin sensitivity, tingling or pins-and-needles sensations, tremors, and unusual pain
• Cluster 7: Shortness of breath and sinus congestion
• Cluster 8: Cough, excessive thirst, and confusion
• Cluster 9: Appetite swings, difficulty regulating body temperature, and increased urinary frequency
• Cluster 10: Red eyes, blurred vision, night sweats, mood swings, and sharp or “ice-pick” pain
• Cluster 11: Abdominal pain, diarrhea, and numbness
• Cluster 12: Excessive tearing or watery eyes, disorientation, and a metallic taste
• Cluster 13: Static-shock sensations and vertigo or dizziness

 

Other Symptoms That Can Occur With CIRS

 

 

The 37-symptom roster doesn’t capture every problem an individual with CIRS may experience. Additional symptoms can emerge from the inflammatory, mitochondrial, hormonal, autonomic, gastrointestinal, and nervous-system changes discussed throughout this article, although these aren’t part of the formal 13-cluster screening tool. 

 

These may include:

 

• Unrefreshing sleep, insomnia, or disrupted sleep-wake rhythms
• Exercise intolerance or disproportionate symptom flares after exertion
• Lightheadedness or orthostatic intolerance, including POTS-like symptoms
• Heart palpitations or abnormal awareness of heartbeat
• Stubborn brain fog or reduced mental stamina beyond the formal cognitive clusters
• Anxiety, depression, irritability, mania, hypochondria, heightened reactivity, or reduced stress tolerance
• Unexplained weight gain, weight loss, or difficulty changing weight despite dietary changes
• Irritable bowel disease, bloating, constipation, reflux, nausea, or increased food reactivity
• New or worsening food, chemical, odor, or environmental sensitivities
• Hormonal symptoms such as reduced libido, menstrual changes, or low-androgen symptoms
• Skin reactions such as itching, flushing, or rashes
• Persistent fatigue or delayed physical recovery that feels disproportionate to activity
• Tinnitus and other ear symptoms

 

These additional symptoms are particularly important clinically because CIRS rarely presents the same way in two individuals. 

 

What Can Make CIRS-Related Inflammation Worse?

 

 

Ongoing or repeated biotoxin exposure remains the primary driver that must be addressed in CIRS, but it’s uncommonly the only source of inflammatory stress affecting the body. 

 

Factors that may worsen CIRS-related inflammation include:

 

• Continued mold or water-damaged-building exposure, including repeated re-exposure during treatment
• Other biotoxin exposures, depending on the individual and environment
• Lyme disease and other vector-borne infections
• Viral, bacterial, fungal, dental (e.g., cavitations), sinus, or other persistent infections
• Mast Cell Activation Syndrome (MCAS), heightened mast-cell reactivity, or histamine intolerance, which can amplify histamine and inflammatory mediator release
• Gut dysfunction, including dysbiosis, increased intestinal permeability, SIBO, SIFO, or gastrointestinal infections
• Autoimmune and other chronic inflammatory conditions
• Poor or inadequate sleep
• Chronic psychological stress or continual fight-or-flight activation
• Overexertion beyond current exercise tolerance
• Physical inactivity and prolonged deconditioning, when movement is otherwise tolerated
• Highly processed foods, high sugar consumption, or foods that consistently provoke symptoms
• Inadequate calories, protein, essential fats, or micronutrients
• Blood-sugar dysregulation and insulin resistance
• Excessive alcohol intake (alcohol isn’t recommended during CIRS treatment)
• Smoking or vaping (including safer forms of nicotine as a supportive tool is highly nuanced)
• Environmental pollutants and toxicants, including wildfire smoke, heavy metals, poor air quality, pesticides, solvents, and other chemical exposures
• Certain medications or immunosuppressive therapies, depending on the individual
• Dehydration or electrolyte imbalance
• Major injury, surgery, acute illness, or other significant physiological stress

 

These factors can create inflammation even outside of CIRS, but when the immune system is already struggling to appropriately regulate and resolve its response, each additional input can add more noise to an already overwhelmed system. 

 

Pro-Tip: Reducing the total inflammatory and toxin burden can be an essential part of CIRS treatment because it limits unnecessary immune noise and creates more capacity for repair. The long-term goal isn’t to build a life around avoiding every possible trigger, but to restore enough immune and nervous-system resilience that everyday exposures can be appropriately recognized, managed, and resolved without triggering an indefinite inflammatory cascade.

 

Carnivore and Anti-Inflammatory Diets for CIRS

 

 

Diet is an important tool for reducing inflammatory burden during CIRS treatment. 

 

Within the Shoemaker Protocol, a low-amylose diet is used particularly when addressing elevated MMP-9, leptin, or PAI-1 rather than as a universal requirement throughout every treatment step. Amylose is a starch concentrated in many higher-glycemic foods, so this approach removes or limits wheat and other cereal grains, rice, oats, barley, rye, potatoes, and most root vegetables, bananas, peanuts, added sugars, corn syrup, and maltodextrin. 

 

The goal is to reduce rapid glucose and insulin excursions that may add another inflammatory input while the underlying CIRS response is being corrected. 

 

In our clinical practice, however, we often go further than a conventional low-amylose diet. Many of our CIRS patients and clients following Carnivore or meat-heavy keto diets enter treatment with better metabolic bloodwork, report better symptom control, and appear to tolerate the protocol more easily. 

 

We consider Carnivore one of the most powerful anti-inflammatory elimination approaches available because it removes many potential dietary irritants while providing highly bioavailable protein, fat, and micronutrients. We have also found that patients eating adequate animal fat and cholesterol may have more nutritional buffers during prolonged use of cholestyramine (CSM) or Welchol, particularly for individuals who can’t fully escape exposure and require binders longer term. 

 

Both medications are bile-acid sequestrants that lower LDL cholesterol, and they can also interfere with absorption of fat-soluble vitamins, making lipid and nutritional monitoring especially important during extended treatment. 

 

This is one area where our clinical experience differs from Shoemaker’s metabolic interpretation. 

 

His concern focuses partly on VDAC and mitochondrial hypometabolism: when inflammatory signaling interferes with normal mitochondrial energy pathways, glucose can still generate a small amount of ATP through glycolysis without relying fully on mitochondrial oxidative metabolism. 

 

From that perspective, some CIRS patients may feel better with carbs available as an alternate fuel source while mitochondrial function is impaired. We do see this in a subset of patients, but we don’t believe it supports a blanket recommendation against keto or Carnivore diets. Many patients tolerate fat-based metabolism very well and experience substantial improvements in inflammation, energy, mental clarity, and treatment stability.

 

Pro-Tip: If you feel and function better with some carbs during CIRS treatment, the goal isn’t to force ketosis or stay dogmatic with diet. We recommend prioritizing organic, whole-food, local, in-season, lower-toxicity, low-amylose carb sources that you tolerate well rather than highly processed starches and sugars. The best therapeutic diet is the one that lowers inflammatory burden, supplies enough energy and nutrients, supports gut and metabolic health, and gives that individual the resilience needed to complete treatment successfully.

 

Why Suppressing Inflammation Isn’t the Same as Resolving It

 

 

Reducing inflammation is an important part of healing, but suppressing inflammatory signals without addressing why they are being generated can leave the underlying problem untouched. In CIRS, inflammation is the body responding to an ongoing or unresolved threat. If exposure and other underlying drivers remain active, simply lowering cytokines or quieting symptoms can mask the signal without correcting the cause.

 

Many therapies can help reduce inflammatory burden or improve symptoms, ranging from personalized supplementation to certain peptides, VIP therapy, nervous-system regulation, and other targeted adjuncts. 

 

These tools can be valuable, especially when they improve function or make treatment more tolerable, but they’re best viewed as bridges rather than replacements for foundational care. Their role is to create enough stability for the body to heal while the deeper drivers are identified and addressed.

 

Since the long-term consequences of perpetual CIRS-related inflammation can affect multiple systems, symptom relief should never be the only endpoint. The goal is to use every appropriate tool within a larger root-cause plan that removes ongoing exposure, lowers total inflammatory burden, restores immune regulation, and builds enough resilience for the body to respond to future stressors without remaining stuck in a chronic inflammatory state.

 

How Do You Reduce Inflammation With CIRS?

 

 

Reducing inflammation in CIRS starts with addressing the reason the inflammatory response remains activated. In our clinical practice, we believe an individualized approach built around the Shoemaker Protocol should form the foundation of treatment.

 

However, CIRS recovery can commonly require additional support. Lowering the total inflammatory burden can give the immune system more capacity to regulate, repair, and respond appropriately. Depending on the individual, supportive strategies may include:

 

• An anti-inflammatory diet: Low-amylose eating is incorporated within the Shoemaker approach, while we often use Carnivore or meat-heavy keto diets to further reduce dietary inflammatory inputs.
• Tolerated movement and exercise: Walking, resistance training, mobility work, or other appropriately paced movement can support circulation, mitochondrial health, and recovery without pushing the body into repeated crashes.
• Support drainage and elimination pathways: Promoting regular bowel movements, bile flow, hydration, kidney function, and lymphatic movement can help the body eliminate mobilized compounds more efficiently, potentially reducing recirculation and the overall inflammatory burden during detox-focused treatment.
• Reducing environmental toxin burden: Prioritize cleaner air and water and make practical, lower-toxicity swaps for personal-care products, cleaning products, fragrances, pesticides, plastics, and other unnecessary exposures.
• Prioritize lipid replacement and gut healing: Supporting cell-membrane lipids with phospholipids and essential fatty acids while strengthening gut-barrier integrity, bile flow, and digestive function can help lower inflammatory burden and create a more resilient gastrointestinal terrain. This can be especially important before and during prescription binders cholestyramine or Welchol, which alter bile-acid recycling and can be difficult for some patients to tolerate.
• Personalized supplementation: Omega-3s, SPMs, phospholipids, electrolytes, antioxidants, minerals, and other targeted supplementation may be useful depending on laboratory findings and individual needs.
• Treating coexisting problems in the right order: MCAS, Lyme and coinfections, MARCoNS, gut dysfunction, SIBO/SIFO, dental infections, and other inflammatory conditions typically need individualized timing so treatment doesn’t overwhelm the patient.
• Supporting the nervous system: Breathwork, mindfulness, limbic-system work, somatic practices, and personalized mind-body programs can help reduce consistent threat signaling while the biological drivers of CIRS are being treated.
• Prioritizing sleep and recovery: Consistent sleep, adequate nutrition, hydration, electrolytes, and appropriate rest provide the basic resources the body needs for inflammatory resolution.
• Using adjunct therapies strategically: Red-light therapy, sauna, HBOT, ozone-based therapies, IV therapy, peptides, and other modalities may help with symptom management or recovery in select patients, but tolerance varies, and these should complement, not replace, foundational treatment.

 

FAQs on CIRS and Inflammation

Here are some of our most frequently asked questions about CIRS and inflammation: